Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Congestive Heart Failure accounts for 12.9% share of global Cardiovascular clinical trial activity in 2020

25 Feb 2021 (Last Updated February 25th, 2021 16:11)

Congestive Heart Failure (Heart Failure) accounted for a 12.9% share of the global clinical trials within the Cardiovascular therapy area in 2020, registering an increase of 2.4% when compared with the last ten-year average of 10.5% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Congestive Heart Failure

Industry sponsored trials held a 45.7% share of all the clinical trials for Congestive Heart Failure indication in 2020, registering an increase of 8.4% when compared with the ten-year average of 37.3%. Non-industry sponsored trials accounted for a 54.3% share in 2020, marking a decrease of 8.4% over the ten-year average of 62.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Congestive Heart Failure trials

Asia-Pacific was the top region for industry sponsored Congestive Heart Failure trials, accounting for a 56.7% share in 2020, when compared with the five-year average of 49.4% and ten-year average of 45.5%.

Europe was at the second position with a 28.9% share in 2020, over the five-year average of 38.3% and ten-year average of 45.4%, followed by North America with a 25.6% share in 2020, as against five-year and ten-year averages of 35.2% and 32.1% respectively.

Middle East and Africa stood fourth with a 6.7% share in 2020, compared with the five-year average of 7.9% and ten-year average of 7.9%, followed by South and Central America with a 3.3% share in 2020, over five-year and ten-year averages of 8.2% and 7.7% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Congestive Heart Failure trials, accounting for a 37.8% share in 2020, as against the five-year average of 26.5% and ten-year average of 18.5%.

The US held a 25.6% share in 2020, over the five-year average of 33.7% and ten-year average of 30.7%, followed by Russia with an 18.9% share in 2020, compared with the five-year and ten-year averages of 15.7% and 21.3% respectively.

Italy held a 6.7% share in 2020, as against the five-year average of 9.7% and ten-year average of 11.6%.

Poland held a 6.7% share in 2020, over the five-year and ten-year averages of 12.0% and 13.4% respectively.

Top regions of non-industry sponsored Congestive Heart Failure trials

Asia-Pacific was the top region for non-industry sponsored Congestive Heart Failure trials, accounting for a 38.9% share in 2020 when compared with the five-year average of 35.8% and ten-year average of 37.0%.

Europe was at the second position with a 32.4% share in 2020, over the five-year and ten-year averages of 29.7% and 31.4% respectively, followed by North America with a 20.4% share in 2020, as against the five-year average of 24.5% and ten-year average of 24.1%.

Middle East and Africa stood at the fourth position with an 8.3% share in 2020, compared with the five-year average of 8.3% and ten-year average of 7.5%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 3.6% and 2.8% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Congestive Heart Failure trials, accounting for a 25.0% share in 2020, as against the five-year average of 14.2% and ten-year average of 9.6%.

The US held an 18.5% share in 2020, over the five-year average of 21.0% and ten-year average of 20.4%, followed by Iran with a 6.5% share, compared with the five-year and ten-year averages of 4.3% and 4.4% respectively.

The UK held a 5.6% share in 2020, as against the five-year average of 5.3% and ten-year average of 5.4%.

South Korea held a 3.7% share in 2020, over the five-year average of 1.5% and ten-year average of 1.7%.

Phase I trials lead industry sponsored clinical trials for Congestive Heart Failure in 2020

Phase I trials held a 62.0% share of industry sponsored clinical trials for Congestive Heart Failure in 2020, over the five-year average of 51.7% and ten-year average of 47.7%.

Phase II trials held a 16.0% share in 2020, as against the five-year average of 20.9% and ten-year average of 26.2%. Phase III trials held a 12.0% share in 2020, compared with the five-year and ten-year averages of 16.1% and 14.7% respectively.

Phase IV trials held a 10.0% share in 2020, over the five-year average of 11.2% and ten-year average of 11.4%.

Phase IV trials lead non-industry sponsored clinical trials for Congestive Heart Failure in 2020

Phase IV trials held a 33.6% share of non-industry sponsored clinical trials for Congestive Heart Failure in 2020, over the five-year average of 37.7% and ten-year average of 32.9%.

Phase II trials held a 31.9% share in 2020, as against the five-year average of 43.2% and ten-year average of 47.0%. Phase I trials held an 18.5% share, compared the five-year and ten-year averages of 7.5% and 7.2% respectively.

Phase III trials held a 16.0% share in 2020, over the five-year average of 11.7% and ten-year average of 12.9%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.